Bedrijfsoverzicht
Geron Corporation is a commercial-stage biopharmaceutical enterprise dedicated to the development of therapeutics specifically targeting oncology applications. The company operates within the broader healthcare sector, functioning specifically in the biotechnology industry where innovation in drug discovery and clinical development defines its business model. As of the latest available data, the organization employs a workforce of 258 individuals and maintains a market capitalization of $1.07B. Its annual revenue generated over the trailing twelve months stands at $183.88M, which positions the firm as a mid-cap entity with significant operational scale relative to its employee base. The market capitalization of $1.07B suggests that the market values the company's intangible assets, including its product pipeline and intellectual property, at a level substantially higher than its current cash holdings alone. The revenue figure of $183.88M indicates a mature but potentially revenue-constrained operation that relies heavily on the successful commercialization of its oncology-focused assets to drive future expansion.
Financiële gezondheid
Geron Corporation reported a revenue of $183.88M for the trailing twelve months, while simultaneously reporting a net income of $-83,500,000 and an EBITDA of $-51,079,000. The substantial gap between the positive revenue of $183.88M and the negative net income of $-83,500,000 reveals a cost structure characterized by high operating expenses, likely driven by research and development costs or commercialization expenditures that exceed gross profitability before interest and taxes. The company generated a free cash flow of $-78,356,248, which indicates a current lack of financial flexibility and suggests that the business is burning cash rather than generating surplus liquidity from its core operations. Despite this cash burn, the balance sheet holds $357.92M in cash against $121.99M in debt, resulting in a debt-to-equity ratio of 54.01. While the absolute debt level is lower than the cash reserves, the high debt-to-equity ratio of 54.01 implies a leveraged capital structure relative to shareholders' equity, though the liquidity cushion provides some buffer. The gross margin stands at an impressive 97.4%, which indicates that the cost of goods sold is negligible compared to revenue, a common trait in the biotechnology sector where primary costs are R&D rather than manufacturing. However, the operating margin is negative at -17.7% and the profit margin is even more negative at -45.4%, highlighting that high fixed costs and R&D investments are eroding the bottom line before accounting for financing costs. The current ratio is 4.66, which indicates a very strong short-term liquidity position where current assets significantly outweigh current liabilities, ensuring the company can meet its immediate obligations without distress. Furthermore, the return on equity is -33.0% and the return on assets is -5.5%, revealing that management is currently generating negative returns on the capital invested in the company. These negative return metrics indicate that the company is not yet profitable and is utilizing shareholder capital to fund growth initiatives that have not yet resulted in positive earnings.
Waarderingsbeoordeling
The company currently has no trailing P/E ratio as earnings are negative, but it trades with a forward P/E of 20.88, which implies that the market is pricing in expected future earnings growth or is valuing the company based on anticipated profitability from its pipeline. The price-to-book ratio is 4.73, indicating that the market values the company at a significant premium of 4.73 times its book value, reflecting the high valuation of its intellectual property and future revenue potential. Additionally, the price-to-sales ratio is 5.82 and the EV/EBITDA is -16.32, which suggests that traditional valuation metrics are skewed by the lack of current profitability and that investors are relying on sales multiples to gauge worth. The stock has traded within a range defined by a 52-week high of $2.01 and a 52-week low of $1.04, placing the current valuation in a context of high volatility relative to its recent trading history. The beta value is 0.67, which means the stock's price volatility is lower than the broader market, suggesting it is less sensitive to general market fluctuations than the average large-cap stock.
Growth & Income
Geron Corporation experienced a revenue growth of 1.0% year-over-year, while earnings growth is not applicable due to negative earnings, implying that the company is not currently expanding its profitability at a faster rate than its revenue. Since the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders but instead retains all capital to reinvest into its research and development pipeline. This reinvestment strategy is typical for biotechnology firms that prioritize growth and product development over income distribution to existing shareholders. The overall growth and income profile reflects a classic early-to-mid-stage biotechnology company that trades on the promise of future value from its oncology pipeline rather than current cash flows or dividend income.